NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Market Benchmark Nifty 50 Records Weakest Performance Since COVID-Hit FY20

The Indian stock market has been under pressure in recent months, with the market benchmark Nifty 50 dropping more than 11% in March, marking its weakest performance since the COVID-hit financial year 2020. The financial year 2025-26 (FY26) ended with a loss of 5%, a decline from the previous year. On Monday, March 30, the Sensex crashed 1,636 points, or 2.22%, to end at 71,947.55, while the Nifty 50 declined 488 points, or 2.14%, to finish at 22,331.40.

The market is facing elevated crude oil prices driven by the West Asian war, a record-low rupee, and massive foreign capital outflow, all of which are keeping the market under pressure. Market experts say the near-term outlook is clouded with uncertainty and recommend maintaining prudence while picking stocks.

Recommended Stocks for the Short Term

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Two market experts, Hitesh Tailor of Choice Broking and Vishnu Kant Upadhyay of Master Capital Services, have recommended the following six stocks to buy for the next 1-2 weeks.

StockPrevious CloseTarget PriceStop Loss
Avenue Supermarts (DMart)₹3,956.80₹4,250₹3,800
Multi Commodity Exchange of India (MCX)₹2,389.40₹2,600₹2,280
Aurobindo Pharma₹1,304.40₹1,425₹1,230
Emcure Pharmaceuticals₹1,595.50₹1,705 and ₹1,740₹1,490
Godawari Power And Ispat (GPIL)₹268.80₹290 and ₹300₹250
NLC India₹268.60₹288 and ₹296₹251

Here are the details of the stock recommendations:

  • Avenue Supermarts (DMart): Hitesh Tailor recommends buying at the current market price with a stop loss at ₹3,800 for a target of ₹4,250.
  • Multi Commodity Exchange of India (MCX): Hitesh Tailor recommends buying at the current market price with a stop loss at ₹2,280 for a target of ₹2,600.
  • Aurobindo Pharma: Hitesh Tailor recommends buying at the current market price with a stop loss at ₹1,230 for a target of ₹1,425.
  • Emcure Pharmaceuticals: Vishnu Kant Upadhyay recommends buying at the current market price with a target of ₹1,705 and ₹1,740 and a stop loss at ₹1,490.
  • Godawari Power And Ispat (GPIL): Vishnu Kant Upadhyay recommends buying at the current market price with a target of ₹290 and ₹300 and a stop loss at ₹250.
  • NLC India: Vishnu Kant Upadhyay recommends buying at the current market price with a target of ₹288 and ₹296 and a stop loss at ₹251.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

The experts have highlighted the technical structure of each stock, including signs of accumulation, breakout patterns, and momentum indicators, to support their recommendations.

Investor Takeaway

Maintain prudence while picking stocks for the short term.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.